576 related articles for article (PubMed ID: 1938759)
21. Flow cytometric immunophenotyping including Bcl-2 detection on fine needle aspirates in the diagnosis of reactive lymphadenopathy and non-Hodgkin's lymphoma.
Laane E; Tani E; Björklund E; Elmberger G; Everaus H; Skoog L; Porwit-MacDonald A
Cytometry B Clin Cytom; 2005 Mar; 64(1):34-42. PubMed ID: 15669024
[TBL] [Abstract][Full Text] [Related]
22. Expression of the NF-kappaB targets BCL2 and BIRC5/Survivin characterizes small B-cell and aggressive B-cell lymphomas, respectively.
Tracey L; Pérez-Rosado A; Artiga MJ; Camacho FI; Rodríguez A; Martínez N; Ruiz-Ballesteros E; Mollejo M; Martinez B; Cuadros M; Garcia JF; Lawler M; Piris MA
J Pathol; 2005 Jun; 206(2):123-34. PubMed ID: 15880597
[TBL] [Abstract][Full Text] [Related]
23. Two monoclonal antibodies defining unique antigenic determinants on human B-lymphoma cells.
Howard DR; Eaves AC; Takei F
Cancer Res; 1985 Dec; 45(12 Pt 1):6322-7. PubMed ID: 2415242
[TBL] [Abstract][Full Text] [Related]
24. Neuron-specific enolase (gamma enolase, gamma-gamma dimer) expression in Hodgkin's disease and large cell lymphomas.
Massarelli G; Onida GA; Piras MA; Marras V; Mura A; Tanda F
Anticancer Res; 1999; 19(5B):3933-8. PubMed ID: 10628334
[TBL] [Abstract][Full Text] [Related]
25. Activation and differentiation antigen expression in B-cell non-Hodgkin's lymphoma.
Salter DM; Krajewski AS; Cunningham S
J Pathol; 1988 Mar; 154(3):209-22. PubMed ID: 3280770
[TBL] [Abstract][Full Text] [Related]
26. CDK9/CYCLIN T1 expression during normal lymphoid differentiation and malignant transformation.
Bellan C; De Falco G; Lazzi S; Micheli P; Vicidomini S; Schürfeld K; Amato T; Palumbo A; Bagella L; Sabattini E; Bartolommei S; Hummel M; Pileri S; Tosi P; Leoncini L; Giordano A
J Pathol; 2004 Aug; 203(4):946-52. PubMed ID: 15258998
[TBL] [Abstract][Full Text] [Related]
27. Immunophenotypic characteristics of T-acute lymphoblastic leukemia cells in relation to DPP IV enzyme expression.
Klobusická M; Babusíková O
Neoplasma; 1998; 45(4):237-42. PubMed ID: 9890667
[TBL] [Abstract][Full Text] [Related]
28. [Non-Hodgkin's malignant lymphomas in primates (immunodiagnostic principles in T-cell lymphomas)].
Indzhiia LV; Iakovleva LA; Chikobava MG; Valentaĭn M; Lapin BA; Klark E
Vestn Akad Med Nauk SSSR; 1990; (9):21-7. PubMed ID: 2264382
[TBL] [Abstract][Full Text] [Related]
29. Non-Hodgkin's lymphomas of primary follicle/mantle zone origin.
Weisenburger DD
Leukemia; 1991; 5 Suppl 1():26-9. PubMed ID: 1716336
[TBL] [Abstract][Full Text] [Related]
30. Dendritic reticulum cell immunoreactivity for low-affinity nerve growth factor receptor in malignant lymphomas.
Dorfman DM; Shahsafaei A
Mod Pathol; 1996 Oct; 9(10):959-65. PubMed ID: 8902831
[TBL] [Abstract][Full Text] [Related]
31. Activated T-cell subsets in benign lymphoid hyperplasias and B-cell non-Hodgkin's lymphomas.
Diaz JI; Edinger MG; Stoler MH; Tubbs RR
Am J Pathol; 1991 Sep; 139(3):503-9. PubMed ID: 1887860
[TBL] [Abstract][Full Text] [Related]
32. Expression of B cell activation antigens on normal and malignant B cells.
Freedman AS; Boyd AW; Berrebi A; Horowitz JC; Levy DN; Rosen KJ; Daley J; Slaughenhoupt B; Levine H; Nadler LM
Leukemia; 1987 Jan; 1(1):9-15. PubMed ID: 3118102
[TBL] [Abstract][Full Text] [Related]
33. Methods in pathology. Identification of T-cell lymphomas in paraffin-embedded tissues using polyclonal anti-CD3 antibody: comparison with frozen section immunophenotyping and genotypic analysis.
Anderson C; Rezuke WN; Kosciol CM; Pastuszak WT; Cartun RW
Mod Pathol; 1991 May; 4(3):358-62. PubMed ID: 1829834
[TBL] [Abstract][Full Text] [Related]
34. Characterization of non-Hodgkin's lymphomas using multiple cell markers. Immunologic, morphologic, and cytochemical studies of 72 cases.
Pinkus GS; Said JW
Am J Pathol; 1979 Feb; 94(2):349-80. PubMed ID: 311589
[TBL] [Abstract][Full Text] [Related]
35. Ki-1 antigen expression defines a favorable clinical subset of non-B cell non-Hodgkin's lymphoma.
Offit K; Ladanyi M; Gangi MD; Ebrahim SA; Filippa D; Chaganti RS
Leukemia; 1990 Sep; 4(9):625-30. PubMed ID: 2168505
[TBL] [Abstract][Full Text] [Related]
36. The usefulness of cell surface markers in predicting the prognosis of non-Hodgkin's lymphomas.
Baird S
Crit Rev Clin Lab Sci; 1993; 30(1):1-28. PubMed ID: 8489735
[TBL] [Abstract][Full Text] [Related]
37. Characterization of postcardiac transplant lymphomas. Histology, immunophenotyping, immunohistochemistry, and gene rearrangement.
Kowal-Vern A; Swinnen L; Pyle J; Radvany R; Dizikes G; Michalov M; Molnar Z
Arch Pathol Lab Med; 1996 Jan; 120(1):41-8. PubMed ID: 8554443
[TBL] [Abstract][Full Text] [Related]
38. Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia.
Xerri L; Chetaille B; Serriari N; Attias C; Guillaume Y; Arnoulet C; Olive D
Hum Pathol; 2008 Jul; 39(7):1050-8. PubMed ID: 18479731
[TBL] [Abstract][Full Text] [Related]
39. Prognostic significance of lymphocytic surface markers and histology in adult non-Hodgkin's lymphoma.
Bloomfield CD; Kersey JH; Brunning RD; Gajl-Peczalska KJ
Cancer Treat Rep; 1977 Sep; 61(6):963-70. PubMed ID: 332359
[TBL] [Abstract][Full Text] [Related]
40. Immunophenotypic and antigen receptor gene rearrangement analysis in T cell neoplasia.
Knowles DM
Am J Pathol; 1989 Apr; 134(4):761-85. PubMed ID: 2495724
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
